Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10


Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.

Massion PP, Healey GF, Peek LJ, Fredericks L, Sewell HF, Murray A, Robertson JF.

J Thorac Oncol. 2017 Mar;12(3):578-584. doi: 10.1016/j.jtho.2016.08.143. Epub 2016 Sep 8.


Serum autoantibody measurement for the detection of hepatocellular carcinoma.

Middleton CH, Irving W, Robertson JF, Murray A, Parsy-Kowalska CB, Macdonald IK, McElveen J, Allen J, Healey GF, Thomson BJ, Ryder SJ, Holdenrieder S, Chapman CJ.

PLoS One. 2014 Aug 5;9(8):e103867. doi: 10.1371/journal.pone.0103867. eCollection 2014.


Signal stratification of autoantibody levels in serum samples and its application to the early detection of lung cancer.

Healey GF, Lam S, Boyle P, Hamilton-Fairley G, Peek LJ, Robertson JF.

J Thorac Dis. 2013 Oct;5(5):618-25. doi: 10.3978/j.issn.2072-1439.2013.08.65.


Application of a high throughput method of biomarker discovery to improvement of the EarlyCDT(®)-Lung Test.

Macdonald IK, Murray A, Healey GF, Parsy-Kowalska CB, Allen J, McElveen J, Robertson C, Sewell HF, Chapman CJ, Robertson JF.

PLoS One. 2012;7(12):e51002. doi: 10.1371/journal.pone.0051002. Epub 2012 Dec 13.


Development and validation of a high throughput system for discovery of antigens for autoantibody detection.

Macdonald IK, Allen J, Murray A, Parsy-Kowalska CB, Healey GF, Chapman CJ, Sewell HF, Robertson JF.

PLoS One. 2012;7(7):e40759. doi: 10.1371/journal.pone.0040759. Epub 2012 Jul 18.


EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays.

Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, Allen J, Thorpe AJ, Hamilton-Fairley G, Parsy-Kowalska CB, MacDonald IK, Jewell W, Maddison P, Robertson JF.

Tumour Biol. 2012 Oct;33(5):1319-26. doi: 10.1007/s13277-012-0379-2. Epub 2012 Apr 11.


EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer.

Lam S, Boyle P, Healey GF, Maddison P, Peek L, Murray A, Chapman CJ, Allen J, Wood WC, Sewell HF, Robertson JF.

Cancer Prev Res (Phila). 2011 Jul;4(7):1126-34. doi: 10.1158/1940-6207.CAPR-10-0328.


Oncogenicity studies of the new serotonin (5-HT)3-receptor antagonist ramosetron in mice and rats.

Tabata H, Sakai T, Miki H, Suzuki H, Ruckman SA, Read RM, Gopinath C, Healey GF, Barker MH, Chasseaud LF, Gazeley MJ, Ince G, Hedge A.

Arzneimittelforschung. 1996 Jun;46(6):560-6.


Effect of age and plasma concentrations of albumin and alpha 1-acid glycoprotein on protein binding of disopyramide.

Holt DW, Hayler AM, Healey GF.

Br J Clin Pharmacol. 1983 Sep;16(3):344-5. No abstract available.


Supplemental Content

Loading ...
Support Center